Inactive

The Department of Veterans Affairs, VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, intends to negotiate on a sole source basis, pursuant to FAR 6.302-1, with Vitalant f... The Department of Veterans Affairs, VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, intends to negotiate on a sole source basis, pursuant to FAR 6.302-1, with Vitalant for national distribution of COVID-19 Convalescent Plasma to provide up to 1200 units of 200mL bags of COVID-19 Convalescent Plasma to support a 24-month VA clinical study using COVID-19 Convalescent Plasma to treat COVID-19 patients. COVID-19 Convalescent Plasma must meet all existing FDA guidelines (subject to change as the COVID-19 Pandemic changes) and come from an approved source. Furthermore, VA-specific requirements limit sources to vendors who can meet International Society of Blood Transfusion (ISBT) format specified in the United States Industry Consensus Standard for the Uniform Labeling of Blood and Blood Components Using ISBT 128 requirements. Vitalant is the only that can provide the plasma meeting all requirements and that can meet the VA requirement for national distribution. This is a notice of intent is not a request for competitive proposals; however, any responsible source who believes it is capable of meeting the requirement may submit a capability statement to the contracting office no later than Thursday, July 24th, 5:00 PM, EST. Interest/capability statements may be sent to Lynn Portman at lynn.portman@va.gov. No telephone responses will be accepted. A determination not to compete the proposed requirement based upon the responses to this notice is solely within the discretion of the Government.